Beam Therapeutics (BEAM) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Denali Therapeutics (DNLI) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 28.6% versus a loss of 1.4%. Over five years, DNLI leads with a -57.9% price change compared with -73.4% for BEAM. Denali Therapeutics is the larger company by market cap ($2.96 billion vs $2.49 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | DNLI |
|---|---|---|
| Share price | $24.13 | $18.52 |
| Market cap | $2.49B | $2.96B |
| 1-day change | -2.58% | -3.34% |
| YTD return | -10.64% | +16.05% |
| 1-year return | -1.43% | +28.59% |
| 5-year return | -73.41% | -57.95% |
| EPS (TTM) | $-0.68 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $139.74M | $0 |
| Revenue growth (YoY) | +120.01% | — |
| Net income (latest FY) | $-79.99M | $-512.54M |
| Operating margin | -274.57% | — |
| Net margin | -57.24% | — |
| 52-week high | $38.26 | $27.30 |
| 52-week low | $20.23 | $13.75 |
| Distance from 52-week high | -36.93% | -32.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.12% | +94.71% |
| Average volume | 1.92M | 1.61M |
| Shares outstanding | 103.29M | 159.85M |
| Employees | 540 | 503 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNLI has outperformed BEAM by 30.0 percentage points over the past year.
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
BEAM vs DNLI FAQ
Which is bigger, Beam Therapeutics or Denali Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $2.96B compared with $2.49B for Beam Therapeutics (BEAM).
Which stock has performed better over the past year, BEAM or DNLI?
DNLI returned +28.59% over the past 12 months, compared with -1.43% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.